文献速递临床试验与 GCP基础与转化研究

维生素C减轻器官功能障碍(LOVIT)随机对照试验方案

Lessening Organ dysfunction with VITamin C (LOVIT): protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-01-08

LOVIT是一项多中心、平行组、盲法、优效性随机对照试验,计划纳入至少800例因脓毒症入住ICU并使用血管升压药的患者,随机接受高剂量静脉维生素C(50 mg/kg每6小时,持续96小时)或安慰剂,主要终点为28天死亡或持续器官功能障碍的复合终点。

要点

  • 高剂量静脉维生素C方案:50 mg/kg每6小时,持续96小时。
  • 主要终点为28天死亡或持续器官功能障碍复合终点。
  • 纳入因脓毒症入ICU并使用血管升压药的患者,排除入ICU超过24小时者。

核心结论

  • 该RCT将提供高剂量静脉维生素C对脓毒症患者重要临床结局影响的证据。

研究设计与样本

  • LOVIT为多中心、平行组、盲法(参与者、临床医生、研究人员、指导委员会成员、数据分析师)、优效性RCT,最小样本量800例。
  • 纳入因脓毒症入住ICU并接受血管升压药的患者,排除入ICU超过24小时者。

关键数值与推荐

  • 干预为高剂量静脉维生素C 50 mg/kg每6小时,持续96小时,或安慰剂。
  • 主要终点为第28天死亡或持续器官功能障碍(需血管升压药、有创机械通气或新发持续肾脏替代治疗)的复合终点。
  • 次要结局包括至第28天持续器官功能障碍无存活天数、6个月死亡率和健康相关生活质量、缺氧、炎症、感染、内皮功能生物标志物及不良事件(溶血、急性肾损伤、低血糖)。
  • 计划进行6项亚组分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sepsis is a health problem of global importance; treatments focus on controlling infection and supporting failing organs. Recent clinical research suggests that intravenous vitamin C may decrease mortality in sepsis. We have designed a randomized controlled trial (RCT) to ascertain the effect of vitamin C on the composite endpoint of death or persistent organ dysfunction at 28 days in patients with sepsis. METHODS: LOVIT (Lessening Organ dysfunction with VITamin C) is a multicenter, parallel-group, blinded (participants, clinicians, study personnel, Steering Committee members, data analysts), superiority RCT (minimum n = 800). Eligible patients have sepsis as the diagnosis for admission to the intensive care unit (ICU) and are receiving vasopressors. Those admitted to the ICU for more than 24 h are excluded. Eligible patients are randomized to high-dose intravenous vitamin C (50 mg/kg every 6 h for 96 h) or placebo. The primary outcome is a composite of death or persistent organ dysfunction (need for vasopressors, invasive mechanical ventilation, or new and persisting renal replacement therapy) at day 28. Secondary outcomes include persistent organ dysfunction-free days to day 28, mortality and health-related quality of life at 6 months, biomarkers of dysoxia, inflammation, infection, endothelial function, and adverse effects (hemolysis, acute kidney injury, and hypoglycemia). Six subgroup analyses are planned. DISCUSSION: This RCT will provide evidence of the effect of high-dose intravenous vitamin C on patient-important outcomes in patients with sepsis. TRIAL REGISTRATION: clinicaltrials.gov, NCT03680274, first posted 21 September 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Masse MH, Ménard J, Sprague S, et al. Lessening Organ dysfunction with VITamin C (LOVIT): protocol for a randomized controlled trial. Trials. 2020. PMID: 31915072. doi:10.1186/s13063-019-3834-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。